Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK4527226 in Early Alzheimer's Disease
NCT06079190Phase 2Terminated
- Sponsor
- GSK
- Start
- Oct 2023
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
Phase 2 trial of nivisnebart, sponsored by GSK. Started Oct 2023; status: terminated.
02
Drugs
nivisnebart
Beyond the preview
Go deeper on NCT06079190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06079190.